摘要
目的观察不同剂量阿托伐他汀和辛伐他汀用于预防对比剂肾病的效果。方法 550例冠状动脉造影患者和350例行经皮冠状动脉介入治疗(PCI)患者,分为空白对照组、阿托伐他汀和辛伐他汀组,其中阿托伐他汀和辛伐他汀组均细分为:小剂量组、中剂量组和大剂量组,并分别给予不同剂量药物口服。观察2组术后血清肌酐(Scr)、内生肌酐清除率(Ccr)变化,以及对比剂肾病发生情况。结果 1术后1、3、5 d,阿托伐他汀不同剂量组患者的Scr水平均显著低于对照组(P<0.05);2术后1、3、5 d,辛伐他汀不同剂量组Scr水平与术前相比,差异无统计学意义(P>0.05);不同剂量组患者Scr水平均低于对照组(P<0.05);3阿托伐他汀和辛伐他汀中、大剂量组对比剂肾病发生率均低于对照组(P<0.01)。结论阿托伐他汀和辛伐他汀均有助于预防对比剂肾病的发生。
Objective To observe the effect of different doses of atorvastatin and simvastatin on prevention of contrast induced nephropathy （CIN）. Methods A total of 550 patients underwent coronary angiography and 350 patients underwent percutaneous coronary intervention were divided into atorvastatin and simvastatin group with different doses of atorvastatin and simvastatin, respec- tively. People in control group did not receive treatment. Changes in serum ereatinine （Scr） and creatinine elearance rate （Ccr） before and after the procedure were observed, and incidence of CIN were compared among groups. Results ① Levels of Scr in different dose atorvastatin groups were lower than those in the control group on day 1, 3, 5 after operation（P〈0.05）. ② There was no significant differenee in level of Ser before and after operation in eaeh simvastatin groups （ P 〉 0.05）. Levels of Scr in different dose simvastatin group were lower than those in the control group on day 1,3,5 after operation（P 〈 0.05）. ③ Overall incidence of CIN in atorvastatin group and sim- vastatin groups were lower than that in the control group（P 〈 0.01）. Conclusion Atorvastatin and simvastatin are beneficial for prevention of CIN.
出处
《实用临床医药杂志》
CAS
2015年第1期49-51,55,共4页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(11321465)
南宁市科技局2012年科研立项项目(20133183)
关键词
对比剂肾病
阿托伐他汀
辛伐他汀
经皮冠状动脉介入治疗
contrast-induced nephropathy
atorvastatin
simvastatin
percutaneous coronary intervention
